Why an aspirin a day no longer keeps the doctor away …

Editorial Focus on: Henry et al. Thromb Haemost2011; 105: 336-344.

• References

• 1 Jack DB. One hundred years of aspirin. Lancet 1997; 350: 437-439.
• 2 Patrono C, Coller B, FitzGerald GA. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-264S.
• 3 Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-1211.
• 4 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372.
• 5 Soejima H, Morimoto T, Saito Y. et al. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. Thromb Haemost 2010; 104: 1085-1088.
• 6 Henry P, Vermillet A, Boval B. et al. 24-hour time dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2010; 105: 336-344.
• 7 Perneby C, Wallen NH, Rooney C. et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658.
• 8 Lordkipanidze M, Pharand C, Schampaert E. et al. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol. 2010 epub ahead of print.
• 9 Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-1218.
• 10 Dragani A, Pascale S, Recchiuti A. et al. The contribution of cyclooxygenase-1 and –2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010; 115: 1054-1061.
• 11 Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
• 12 Grove EL, Hvas AM, Mortensen SB. et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost. 2010 epub ahead of print.
• 13 Cesari F, Marcucci R, Caporale R. et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99: 930-935.
• 14 Rocca B, Santilli F, Pitocco D. et al. Variability in the recovery rate of platelet cyclooxygenase activity during chronic therapy with low-dose aspirin in type 2 diabetes. Circulation 2010; 122: A12233 (Abstract).
• 15 Spectre G, Arnetz L, Stalesen R. et al. Better platelet inhibition in whole blood is achieved by twice daily dosing of aspirin in patients with type 2 diabetes mellitus. Circulation 2010; 122: A15018 (Abstract).
• 16 Grove EL, Hvas AM, Johnsen HL. et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
• 17 Blais N, Pharand C, Lordkipanidze M. et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 2009; 102: 404-411.
• 18 Brambilla M, Parolari A, Camera M. et al. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost 2010; 103: 516-524.
• 19 Mateos-Caceres PJ, Macaya C, Azcona L. et al. Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thromb Haemost 2010; 103: 160-170.
• 20 Pettinella C, Romano M, Stuppia L. et al. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thromb Haemost 2009; 101: 687-690.